The LANCL2 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte line, generated through targeted disruption of the LANCL2 gene. This heterogeneous loss-of-function model abolishes functional LANCL2 protein expression across the cell pool, providing a robust tool for pooled functional studies and high-throughput screening applications without the clonal selection artifacts associated with monoclonal lines.
The Raji host cell line is an EBV-positive Burkitt’s lymphoma-derived B lymphocyte line extensively utilized in immunological and oncological research. These suspension cells express characteristic B cell surface markers and are well-established models for studying humoral immunity, antigen presentation, and B cell malignancies, enabling investigation of lymphomagenesis and therapeutic responses in a human lymphoid context.
LANCL2 functions as a membrane receptor for the plant hormone abscisic acid (ABA) and lantibiotics such as nisin. Upon ligand binding, LANCL2 couples to G??i proteins, leading to adenylate cyclase activation and increased intracellular cAMP. This triggers protein kinase A (PKA) and MAPK/ERK signaling, promoting GLUT4 translocation for glucose uptake and exerting anti-inflammatory effects by inhibiting NF-??B activity. Consequently, LANCL2 signaling suppresses pro-inflammatory cytokines including TNF-?? and IL-6, positioning this receptor at the intersection of metabolic and immune regulation.
Within the Raji B lymphocyte context, LANCL2 knockout disrupts ABA- and lantibiotic-induced cascades, enabling dissection of the receptor??s specific contributions to B cell physiology and lymphomagenesis. This model is particularly relevant for investigating how LANCL2-dependent pathways modulate B cell survival, proliferation, and immune function. Given the gene??s links to type 2 diabetes mellitus and inflammatory bowel disease, these cells offer a simplified platform for exploring disease mechanisms in a B lymphoid environment.
The LANCL2 Knockout Raji Polyclonal Cells are suited for mechanistic studies of LANCL2 signaling, high-throughput screening of agonists or antagonists, and functional analyses of B cell responses in lymphoma models. Researchers can employ Western blotting to confirm LANCL2 ablation, cAMP ELISA to assess proximal signaling, fluorescent deoxyglucose uptake assays to measure glucose transport, and cytokine ELISAs to evaluate NF-??B-driven inflammatory outputs. These cells also serve as an isogenic control for validating LANCL2 as a therapeutic target. For additional technical information, please contact Ascent Research.
